JBI-589
JBI-589 is a non-covalent PAD4 isoform-selective inhibitor with oral bioavailability. JBI-589 reduces CXCR2 expression and blocks neutrophil chemotaxis. JBI-589 reduces primary tumor and metastases, and enhances the anti-tumor effect of checkpoint inhibitors. JBI-589 can be used in cancer research[1][2].
Product Specifications
CAS Number
2308504-22-3
UNSPSC
12352005
Target
Protein Arginine Deiminase
Type
Reference compound
Related Pathways
Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/jbi-589.html
Concentration
10mM
Purity
99.75
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CC(N1C(C=C(C=C1)C(N2C[C@@H](CCC2)N)=O)=N3)=C3C4=CC5=CC=CC=C5N4CC6=CC=C(C=C6)F
Molecular Formula
C29H28FN5O
Molecular Weight
481.56
References & Citations
[1]Deng H, et al. A Novel Selective Inhibitor JBI-589 Targets PAD4-Mediated Neutrophil Migration to Suppress Tumor Progression. Cancer Res. 2022 Oct 4;82 (19) :3561-3572.|[2]Gajendran C, et al. Alleviation of arthritis through prevention of neutrophil extracellular traps by an orally available inhibitor of protein arginine deiminase 4. Sci Rep. 2023 Feb 23;13 (1) :3189.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
GTR15298815 1 Vial
Lentiviral human ANKEF1 shRNA (UAS) - Lentiviral human ANKEF1 shRNA (UAS, RFP) (100)
Sign In for Pricing
View Details 